Cargando…

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jun, Hong, Xiaonan, Song, Yu Qin, Hodkinson, Brendan, Balasubramanian, Sriram, Wang, Songbai, Zhang, Qingyuan, Shi, Yuankai, Huang, Huiqiang, Zhang, Huilai, Zhu, Yan, Shreeve, Stephen Martin, Sun, Steven, Wang, Ze, Wang, Xiaocan, Fan, Yue, Wilson, Wyndham, Vermeulen, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Haematologic Malignancy ‐ Lymphoid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713042/ https://www.ncbi.nlm.nih.gov/pubmed/36467814 http://dx.doi.org/10.1002/jha2.517

Ejemplares similares

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
por: Hillmen, Peter, et al.
Publicado: (2021)

A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
por: Mato, Anthony, et al.
Publicado: (2023)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Targetable alterations in primary extranodal diffuse large B‐cell lymphoma
por: Weissinger, Stephanie E., et al.
Publicado: (2022)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
por: Bock, Theresa, et al.
Publicado: (2022)

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2022)

A nomogram prognostic model for diffuse large B‐cell lymphoma based on SUVmax and GNRI in elderly patients
por: Li, Maoqin, et al.
Publicado: (2023)

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL
por: Fatima, Narjis, et al.
Publicado: (2021)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
por: García, Rolando, et al.
Publicado: (2022)

Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
por: Bishton, Mark J., et al.
Publicado: (2022)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
por: Karmali, Reem, et al.
Publicado: (2022)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

Characteristics and prognosis of distant metastasis after primary treatment for early‐stage extranodal nasal‐type natural killer/T‐cell lymphoma from the China Lymphoma Collaborative Group database
por: Zheng, Xuan, et al.
Publicado: (2022)

First‐line antibiotic treatment in patients with localized extragastric mucosa‐associated lymphoid tissue lymphoma
por: Yao, Ming, et al.
Publicado: (2022)

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication
por: Wang, Chaoyu, et al.
Publicado: (2022)

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
por: Brown, Jennifer R., et al.
Publicado: (2018)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Immune reconstitution in children following chemotherapy for acute leukemia
por: Williams, Anthony P., et al.
Publicado: (2020)

The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia
por: Bhavsar‐Bhakta, Preeya, et al.
Publicado: (2021)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Marginal zone lymphoma expression of histidine‐rich glycoprotein correlates with improved survival
por: Persson Skare, Tor, et al.
Publicado: (2020)

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study
por: Dinnessen, Manette A.W., et al.
Publicado: (2020)

Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome
por: Shen, Yandong, et al.
Publicado: (2021)

Efficacy and tolerability of a modified pediatric‐inspired intensive regimen for acute lymphoblastic leukemia in older adults
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sbjgajhih3up01g7e1tgli46gb